This functional divergence informs distinct therapeutic strategies: interventions targeting OTUB1 prioritize immunomodulation and migration inhibition, whereas USP7-focused therapies aim to restore tumor suppressor function and block pro-proliferative signaling (10). The gene discussed is USP7; the disease is neoplasm.